Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Ceraxa(神经酰胺纳米脂质体)和长春花碱用于改善复发性或难治性急性髓系白血病的治疗
基本信息
- 批准号:10547050
- 负责人:
- 金额:$ 99.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-14 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Myelocytic LeukemiaAdverse effectsAdverse eventAftercareAmendmentAnimalsApoptoticAutophagocytosisAwardBiological MarkersCancer CenterCancer ModelCell DeathCeramidesChloroquineClinicalClinical ResearchClinical TrialsDataDisease ProgressionDisease remissionDoseDose-LimitingDrug KineticsEffectivenessErythrocytesFoundationsFundingGenomicsGrantHistone DeacetylaseHydrophobicityIn VitroInstitutional Review BoardsLegal patentLipidsMediatingMedicalMembraneMemorial Sloan-Kettering Cancer CenterMetabolismMethodsMicrotubulesN-caproylsphingosineNCI-Designated Cancer CenterOrphan DrugsParticipantPathogenesisPatientsPharmaceutical PreparationsPhasePhysiologicalPlasmaPlatelet TransfusionPrivatizationPrognosisPrognostic MarkerProteomicsProtocols documentationPublishingQuality of lifeRefractoryRegimenRelapseResearchResearch PersonnelRunningSamplingSiteSolid NeoplasmSpecialistSphingolipidsSphingosineSupportive careSurrogate MarkersSurvival RateSystemTestingTherapeuticTherapeutic InterventionTimeToxic effectTreatment EfficacyUnited States National Institutes of HealthUniversitiesUniversity of Virginia Cancer CenterValidationVinblastineVirginiabaseclinical investigationcombinatorialcostdesigndrug candidateeffective therapyimprovedin vivoinhibitorinnovationleukemia treatmentlipidomicsliposomal deliverynanonanoliposomenovelnovel strategiesnovel therapeuticspatient biomarkersphase 1 studyphase I trialphase II trialpre-clinicalpredictive markerprognosticrelapse patientsresearch clinical testingsafety testingsphingosine 1-phosphatesuccesstherapeutic biomarkertraffickingtranslational medicinetrial designvirtual
项目摘要
ABSTRACT: This grant supports the clinical study of Keystone Nano’s (KN) Ceraxa (C6 Ceramide
NanoLiposome) and Vinblastine (VBL) in patients with relapsed/refractory Acute Myeloid Leukemia (AML) at
leading NCI cancer centers. A recently completed NCI-supported Phase 1 study in solid tumor patients (NCT
02834611) has shown no Dose Limiting Toxicities and only modest adverse events with Ceraxa at doses up to
323 mg/m2, a dose five times the planned dose for the proposed AML trial. The rationale for the proposed unique
and innovative combinatorial strategy of administration of Ceraxa plus Vinblastine is based upon findings from a
recently renewed NIH NCI P01 grant (CA171983-06A1) awarded to KN Chief Technical Officer and co-founder,
Dr. Mark Kester, where dysfunctional sphingolipid metabolism was shown to contribute to the pathogenesis of
AML. Published mechanistic data document that Vinblastine disrupts autophagy leading to the induction of
Ceraxa-mediated autophagic-cell death and shunting Ceraxa metabolism into pro-apoptotic sphingolipid
metabolites. The objectives of this grant are to: 1) establish a recommended dose of Ceraxa for AML patients
and test preliminary efficacy as a monotherapy, 2) establish a Recommended Phase 2 Dose to test Ceraxa in
combination with Vinblastine, and 3) test the safety of Ceraxa plus Vinblastine at the RP2D. Secondary
objectives of the grant are to: 1) obtain estimates of effectiveness (CR, PR), 2) assess the pharmacokinetics
(PK) of Ceraxa and VBL, 3) obtain estimates of the overall survival (OS) at 90 days after treatment with the
combination of Ceraxa and VBL, 4) validate putative lipid-based prognostic or therapeutic biomarkers from
patient plasma samples; 5) determine the number of red blood cell (RBC) and platelet transfusions needed for
supportive care, and 6) estimate the quality of life of participants prior, during, and following treatment with
Ceraxa and VBL. KN has an open IND 142902 and IRB approval (IRB-HSR 22000) for the monotherapy study.
This grant integrates important translational medicine opportunities – with three research universities, a
company, a supporting PO1 team, and a private foundation (Commonwealth Foundation of Virginia)
cooperatively conducting research and clinical investigations including exploring genomic, proteomic, and
lipidomic impacts of a new AML treatment with a smart clinical trial. All studies will be completed through two
specific aims: 1) Manufacture Ceraxa as a Clinical Drug Product; 2) Conduct Ceraxa clinical trials for AML
patients at leading cancer centers.
摘要:这项资助支持Keystone Nano(KN)Ceraxa(C6神经酰胺)的临床研究
纳米脂质体联合长春花碱治疗复发/难治性急性髓系白血病
领先的NCI癌症中心。最近完成的一项由NCI支持的实体肿瘤患者(NCT)1期研究
02834611)没有显示出剂量限制毒性,并且只有轻微的不良反应,Ceraxa的剂量达到
323 mg/m2,是拟议的急性髓细胞白血病试验计划剂量的五倍。提议的独一无二的
Ceraxa加长春花碱的创新组合给药策略是基于一项
最近续签了NIH NCI P01奖金(CA171983-06A1),授予KN首席技术官兼联合创始人,
马克·凯斯特博士,他的鞘脂代谢障碍被证明参与了脑膜瘤的发病机制
AML。发表的机械数据文件表明长春花碱扰乱自噬导致诱导
Ceraxa介导的自噬细胞死亡和Ceraxa代谢向促凋亡鞘磷脂的分流
代谢物。这笔赠款的目标是:1)为急性髓细胞白血病患者建立一个推荐剂量的Ceraxa
和测试作为单一疗法的初步疗效,2)建立推荐的第二阶段剂量以测试Ceraxa在
与长春花碱联合,以及3)在RP2D处测试Ceraxa与长春花碱的安全性。次要的
赠款的目的是:1)获得疗效评估(CR,PR),2)评估药物动力学
Ceraxa和VBL的(PK),3)获得治疗后90天的总生存期(OS)的估计
Ceraxa和VBL的组合,4)验证了推测的基于脂质的预后或治疗生物标记物
患者血浆样本;5)确定需要输注的红细胞(RBC)和血小板数量
支持性护理,以及6)评估参与者在治疗前、治疗中和治疗后的生活质量
Ceraxa和Vbl。KN拥有开放的IND 142902和IRB批准(IRB-HSR 22000)进行单一疗法研究。
这笔赠款整合了重要的转化医学机会-与三所研究型大学、一所
公司、支持PO1团队和私人基金会(弗吉尼亚联邦基金会)
合作开展研究和临床调查,包括探索基因组、蛋白质组和
一项具有SMART临床试验的新AML治疗方法对血脂的影响。所有的学习将在两个月内完成
具体目标:1)将Ceraxa作为临床药物产品生产;2)对AML进行Ceraxa临床试验
领先癌症中心的病人。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bernadette McMahon Adair其他文献
Bernadette McMahon Adair的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bernadette McMahon Adair', 18)}}的其他基金
Ceraxa (Ceramide NanoLiposome) and Vinblastine For the Improved Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Ceraxa(神经酰胺纳米脂质体)和长春花碱用于改善复发性或难治性急性髓系白血病的治疗
- 批准号:
10704116 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 99.96万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 99.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 99.96万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 99.96万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 99.96万 - 项目类别:
Discovery Grants Program - Individual